6.8  -0.2 (-2.86%)		06-24 16:00
Open: 7.02 High: 7.195 Volume: 92,543		Pre. Close: 7 Low: 6.76 Market Cap: 84(M)

Short term
Mid term
Targets	6-month :	8.39	1-year :	8.98
Resists	First :	7.18	Second :	7.69
Pivot price	6.89
Supports	First :	6.38	Second :	5.3
MAs	MA(5) :	6.96	MA(20) :	6.99
	MA(100) :	6.73	MA(250) :	4.49
MACD	MACD :	-0.2	Signal :	-0.2
%K %D	K(14,3) :	60.4	D(3) :	59.3
RSI	RSI(14): 43.6
52-week	High :	9.32	Low :	2.19

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ NRXS ] has closed above bottom band by 37.7%. Bollinger Bands are 49.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	7.2 - 7.24	7.24 - 7.27
Low:	6.65 - 6.7	6.7 - 6.73
Close:	6.73 - 6.8	6.8 - 6.86

NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.

Thu, 18 Jun 2026
Neuraxis Inc (NRXS) Valuation: PE, PB & Fair Value Analysis - TradingKey

Sat, 13 Jun 2026
NeurAxis Stockholders Approve Directors and Equity Compensation Plans - The Globe and Mail

Mon, 18 May 2026
NeurAxis (NRXS) Climbs on Reimbursement and Guideline Momentum - Yahoo Finance

Wed, 13 May 2026
Craig-Hallum Sticks to Its Buy Rating for NeurAxis, Inc. (NRXS) - The Globe and Mail

Tue, 12 May 2026
Neuraxis, INC 1Q 2026: Revenue $1.61M, EPS $(0.18) — 10-Q Summary - TradingView

Wed, 22 Apr 2026
NeurAxis Expands Payer Coverage with Four New Medical Policies - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.